Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.
作者信息
Kleppe Maria, Koche Richard, Zou Lihua, van Galen Peter, Hill Corinne E, Dong Lauren, De Groote Sofie, Papalexi Efthymia, Hanasoge Somasundara Amritha V, Cordner Keith, Keller Matthew, Farnoud Noushin, Medina Juan, McGovern Erin, Reyes Jaime, Roberts Justin, Witkin Matthew, Rapaport Franck, Teruya-Feldstein Julie, Qi Jun, Rampal Raajit, Bernstein Bradley E, Bradner James E, Levine Ross L
出版信息
Cancer Cell. 2018 Apr 9;33(4):785-787. doi: 10.1016/j.ccell.2018.03.024.
Abstract
摘要
相似文献
1
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.致癌激活和炎症信号的双重靶向增强骨髓增殖性肿瘤的治疗效果。
Cancer Cell. 2018 Apr 9;33(4):785-787. doi: 10.1016/j.ccell.2018.03.024.
2
BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms.双重 JAK/BET 抑制作为骨髓增殖性肿瘤治疗策略的研究进展。
Cancer Cell. 2018 Jan 8;33(1):3-5. doi: 10.1016/j.ccell.2017.12.007.
3
Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.伊马替尼及其他——靶向骨髓增殖性疾病中活化的酪氨酸激酶
Onkologie. 2012;35 Suppl 1:34-41. doi: 10.1159/000334824. Epub 2012 Jan 20.
4
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.针对骨髓增生性肿瘤中 PI3K/Akt/mTOR 通路的治疗策略。
Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S307-9. doi: 10.1016/j.clml.2013.07.011.
5
Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.野生型Kras的缺失促进了致癌性Kras诱导白血病发生过程中所有Ras异构体的激活。
Leukemia. 2016 Jul;30(7):1542-51. doi: 10.1038/leu.2016.40. Epub 2016 Feb 29.
6
Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.致癌性和野生型 Ras 在调节有丝分裂原激活的蛋白激酶信号转导中发挥不同的作用。
Cancer Discov. 2013 Jan;3(1):112-23. doi: 10.1158/2159-8290.CD-12-0231. Epub 2012 Oct 25.
7
The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.血液系统疾病中JAK2突变与易位的研究历程：发病机制、诊断与治疗前景，以及世界卫生组织对骨髓增殖性肿瘤的修订诊断标准
Hum Pathol. 2008 Jun;39(6):795-810. doi: 10.1016/j.humpath.2008.02.004.
8
Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders.中心体靶向酪氨酸激酶活性并不能增强慢性骨髓增殖性疾病的致癌性。
Leukemia. 2012 Apr;26(4):728-35. doi: 10.1038/leu.2011.283. Epub 2011 Oct 21.
9
Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.W515位点的17种突变导致MPL/血小板生成素受体的致癌激活：对骨髓增殖性肿瘤的影响
Leukemia. 2016 May;30(5):1214-6. doi: 10.1038/leu.2015.271. Epub 2015 Oct 6.
10
Bone morbidity in chronic myeloproliferative neoplasms.慢性骨髓增殖性肿瘤中的骨病变
Expert Rev Hematol. 2015 Aug;8(4):447-56. doi: 10.1586/17474086.2015.1053456. Epub 2015 Jun 2.
引用本文的文献
1
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.髓系癌症中表观遗传靶分子与疗法的演变格局：聚焦急性髓系白血病和骨髓增殖性肿瘤
Leukemia. 2025 May 15. doi: 10.1038/s41375-025-02639-x.
2
Suppressed activation of the IRF7 and TLR9 by JAK2V617F gold nanoparticles.JAK2V617F金纳米颗粒抑制IRF7和TLR9的激活。
Immunogenetics. 2025 Feb 28;77(1):16. doi: 10.1007/s00251-025-01374-y.
3
Novel approaches in myelofibrosis.骨髓纤维化的新方法。
Hemasphere. 2024 Dec 12;8(12):e70056. doi: 10.1002/hem3.70056. eCollection 2024 Dec.
4
Targeting treatment resistance: unveiling the potential of RNA methylation regulators and TG-101,209 in pan-cancer neoadjuvant therapy.靶向治疗抵抗：揭示 RNA 甲基化调节剂和 TG-101,209 在泛癌新辅助治疗中的潜力。
J Exp Clin Cancer Res. 2024 Aug 19;43(1):232. doi: 10.1186/s13046-024-03111-x.
5
Mapping genotypes to chromatin accessibility profiles in single cells.在单细胞中对基因型进行作图以获得染色质可及性图谱。
Nature. 2024 May;629(8014):1149-1157. doi: 10.1038/s41586-024-07388-y. Epub 2024 May 8.
6
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.SHP2 抑制在骨髓增殖性肿瘤的临床前模型中作为单药治疗和与 JAK2 抑制联合显示疗效。
Am J Hematol. 2024 Jun;99(6):1040-1055. doi: 10.1002/ajh.27282. Epub 2024 Mar 5.
7
IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.白细胞介素-1β（IL-1β）通过促进 JAK2 突变造血干细胞的早期克隆扩张，促进 MPN 疾病的起始。
Blood Adv. 2024 Mar 12;8(5):1234-1249. doi: 10.1182/bloodadvances.2023011338.
8
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations.骨髓纤维化中 JAK 抑制作用的不断发展：单药治疗和联合治疗。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):667-675. doi: 10.1182/hematology.2023000452.
9
Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins.米氏内酯通过与信号转导和转录激活因子3/5（STAT3/5）蛋白共价结合，抑制STAT3/5磷酸化，从而对骨髓增殖性肿瘤发挥作用。
Blood Sci. 2023 Jul 12;5(4):258-268. doi: 10.1097/BS9.0000000000000168. eCollection 2023 Oct.
10
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms.骨髓增殖性肿瘤的恶性克隆中细胞衰老加速。
Blood Cancer J. 2023 Nov 6;13(1):164. doi: 10.1038/s41408-023-00936-1.
Zotero 插件